DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for spondylosis — screening already-approved drugs against its 19-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSpondylosis maps to a 19-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for spondylosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
PDZ domain containing 8 (PDZD8) — PDZD8 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7F6J · 2.1 Å · ligand GUANOSINE-5'-TRIPHOSPHATE (GTP). Experimental structure, not a prediction.
What the evidence adds up to
The evidence base for treating spondylotic myelopathy is dominated by surgical case series with no controlled comparisons against conservative care. A 1973 report on 35 patients treated with extensive laminectomy and dentate ligament section found that after one to seven years, 24 maintained distinct improvement, nine were unchanged, and two worsened. A 1988 retrospective analysis of 206 patients treated over seven years by either anterior or posterior approaches concluded that similarly good results could be obtained by either route if the procedure was tailored to the cause and extent of the problem. A 2021 single-case report of cervical spondylolysis with myelopathy described a good outcome after posterior decompression and circumferential fixation.
Earlier literature is explicitly cautious. A 1960 review stated that published results of treatment, particularly for myelopathy, remain disappointing, and noted disagreement between marked conservatism and radical surgery. A 2021 editorial reiterates that cervical spondylotic myelopathy remains a clinical diagnosis, its natural history is unclear, and treatment is controversial, especially for mild or moderate disease without rapid progression. A 2019 case series of three patients with cervical spondylotic myelopathy, assessed twice at different times, describes wide variability in physiotherapeutic interventions according to signs and symptoms, but provides no outcome data beyond descriptive comparison of severity and affected regions.
Diagnostic imaging literature from 1963 addresses lumbar spondylosis, not cervical disease, and reports that multiple constrictions of the Pantopaque column on upright myelography are characteristic, with the most frequently involved levels being L4–5, L3–4, and L2–3, in contrast to disc herniation at L4–5 and L5–S1. No abstract in this set reports any drug treatment, repurposed or otherwise, for spondylosis. What is missing is any randomised trial comparing surgery with non-operative management, any prospective natural history study, and any pharmacological intervention tested in this condition; patient stratification by severity and progression rate remains undefined.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of neurosurgery · 1973 · 86 citations
Results of adequate posterior decompression in the relief of spondylotic cervical myelopathy
Abstract✓ The author reports his experience with 35 cases of spondylotic myelopathy treated by extensive laminectomy and section of the dentate ligament. After a follow-up of 1 to 7 years, 24 patients have maintained distinct improvement; in nine the disability has not improved and in two it has become worse. The technique is described, and postoperative myelograms are used to demonstrate the improvement.
AbstractIn spite of much work on cervical spondylosis in the past ten years, the published results of treatment, parti- cularly in cases of myelopathy, remain disappointing. Opinions vary regarding the right policy, from marked conservatism to radical surgery. Classification Some confusion arises from failure to distinguish between the main types of lesion found in association with cervical spondylosis in assessing results. These may be classified under four headings.
AbstractSummary The surgical approach to the treatment of cervical spondylitic myelopathy has been one of major controversy, both clinically and in the literature. We present here the results of a retrospective analysis of 206 patients treated by the authors over a 7-year period by either a posterior or anterior approach. Our results suggest that if the procedure is tailored to the cause as well as extent of the problem, similarly good results can be obtained by either surgical approach.
British Journal of Radiology · 1963 · 25 citations
Myelographic Findings in Spondylosis of the Lumbar Spine
AbstractLumbar spondylosis can produce nerve root or cauda equina compression. The hypertrophic facet joints, laminal processes and osteophytes of spondylosis may produce defects both at the anterior, posterior and lateral margins of the Pantopaque column in myelography. Multiple constrictions of the oil column in upright lumbar myelography are characteristic features of spondylosis. Differentiating myelographic features of spondylosis from herniation of intervertebral disc are discussed, and 11 illustrated cases are presented. In lumbar spondylosis, the most frequently involved areas, in order of their sequence, are L4–5, L3–4 and L2–3; whereas in herniation of the nucleus pulposus they are L4–5 and L5–S1.
CERVICAL SPONDYLOTIC MYELOPATHY: CLINICAL CASES AND PHYSIOTHERAPY
AbstractABSTRACT The aims of this article are to present cervical spondylotic myelopathy, a spinal condition caused by bony, ligament and disc alterations that results in spinal cord compression leading to progressive degeneration of the spinal cord, and to describe the possible physiotherapeutic interventions. The pathology has different forms of progression and affected areas, which contributes to the diversity of clinical presentations. This work presents two evaluations of three patients diagnosed with this disease, at different times, to compare the severity, the affected regions, and the evolution of each one. Subsequently, it describes the most appropriate physiotherapeutic treatment for this illness, demonstrating its wide variability according to the signs and symptoms presented. Level of Evidence: IV. Case series.
A Surgical Case of Spondylolysis of the Sixth Cervical Vertebra with Myelopathy
AbstractLumbar spondylolysis is a relatively common disease that affects approximately 5% of the general population. However, cervical spondylolysis is a rare condition, with only approximately 100 cases reported to date. Herein, we report the case of a patient with cervical spondylolysis who developed myelopathy, for whom posterior decompression and circumferential fixation was performed, resulting in a good outcome.
European Journal of Hospital Pharmacy · 2021 · 0 citations · open access
Welcome to this online edition
Abstract<h3>Summary</h3> Cervical spondylotic myelopathy (CSM) is the leading cause of myelopathy in patients over age 50 years. Despite advances, CSM remains a clinical diagnosis and its natural history remains unclear. The treatment of CSM is controversial, especially in patients with mild or moderate clinical disease without rapid progression of symptoms. Herein, we begin with a clinical vignette followed by a brief description of the clinical problems. We discuss evaluation, treatment, and recommendations for the treatment of CSM. Emphasis is drawn to areas of uncertainty and present level of evidence for the treatment modalities of CSM.
CERVICAL SPONDYLOTIC MYELOPATHY: CLINICAL CASES AND PHYSIOTHERAPY
AbstractABSTRACT The aims of this article are to present cervical spondylotic myelopathy, a spinal condition caused by bony, ligament and disc alterations that results in spinal cord compression leading to progressive degeneration of the spinal cord, and to describe the possible physiotherapeutic interventions. The pathology has different forms of progression and affected areas, which contributes to the diversity of clinical presentations. This work presents two evaluations of three patients diagnosed with this disease, at different times, to compare the severity, the affected regions, and the evolution of each one. Subsequently, it describes the most appropriate physiotherapeutic treatment for this illness, demonstrating its wide variability according to the signs and symptoms presented. Level of Evidence: IV. Case series.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
